GlassScriptPhysician profile
Leonard Cheung Lim
NPI 1104106368
$11,102.32
in general payments reported to CMS, 2019-2025
40 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $1,073 · 2021: $1,687 · 2022: $1,797 · 2023: $1,647 · 2024: $1,537 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,152 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,151.91 |
| Education | $107.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,626.90 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,535.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,339.19 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Genzyme Corporation | $972.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $825.26 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $776.62 | 2019-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $424.88 | 2019-2024 | Yupelri |
| Gilead Sciences, INC. | $408.85 | 2021-2024 | Veklury |
| Merck Sharp & Dohme LLC | $368.17 | 2020-2025 | Winrevair, Recarbrio, Zerbaxa |
| Insmed, INC. | $315.12 | 2019-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $306.98 | 2025 | Ohtuvayre |
| Amgen INC. | $226.65 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $190.61 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $181.13 | 2020-2025 | Glassia |
| Genentech USA, INC. | $180.56 | 2019-2025 | Xolair |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.